Effects of GLP-1 (glucagon‑like peptide‑ 1) on liver

Authors: J. Fontana 1;  Z. Červinková 2;  M. Anděl 1
Authors‘ workplace: Centrum pro výzkum diabetu, metabolizmu a výživy 3. lékařské fakulty UK a FN Královské Vinohrady, Praha, vedoucí centra prof. MU Dr. Michal Anděl, CSc. 1;  Ústav fyziologie Lékařské fakulty UK v Hradci Králové, přednostka prof. MU Dr. Zuzana Červinková, CSc. 2
Published in: Vnitř Lék 2013; 59(7): 551-558


Effects of glucagon‑like peptide 1 (GLP‑1) on liver cells are very intensively studied. In the metabolism of saccharides GLP‑1 stimulates synthesis of glycogen and reduces glucose production –  thus acting like insulin. In the lipid metabolism it enhances fatty acid oxidation and lipid transport from hepatocytes while reducing de novo lipogenesis –  effects more similar to glucagon action. Some studies suggest beneficial effects of GLP‑1 on oxidative stress, endoplasmic reticulum stress, production of inflammatory mediators and dysfunction of biliary secretion. Current results suggest that drugs affecting incretin system could be used in the treatment of certain liver diseases (e.g. NAFLD and NASH) in the future. In the following article we mention the known effects of GLP‑ 1 on liver functions and liver metabolism and we point out its possible future therapeutic use in the treatment of liver diseases.

Key words:
glucagon‑like peptide 1 –  incretins –  liver –  non‑alcoholic fatty liver disease –  fatty liver –  metabolism of saccharides –  metabolism of lipids


1. Hugo J, Vokurka M. Velký lékařský slovník. Praha: Maxdorf 2009.

2. La Barre J. Sur les possibilite’s d’un traitement du diabe’te par l’incre’tine. Bull Acad R Med Belg 1932; 12: 620– 634.

3. Brown JC, Mutt V, Pederson RA. Further purification of a polypeptide demonstrating enterogastrone activity. J Physiol 1970; 209: 57– 64.

4. Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983; 302: 716– 718.

5. Bell GI, Sanchez‑ Pescador R, Laybourn PJ et al. Exon duplication and divergence in the human preproglucagon gene. Nature 1983; 304: 368– 371.

6. McIntyre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. Lancet 1964; 2: 20– 21.

7. Elrick H, Stimmler L, Hlad CJ Jr et al. Plasma insulin responses to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964; 24: 1076– 1082.

8. Creutzfeldt W. The [pre‑] history of the incretin concept. Regul Pept 2005; 128: 87– 91.

9. Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C‑ peptide responses. J Clin Endocrinol Metab 1986; 63: 492– 498.

10. Kreymann B, Williams G, Ghatei MA et al. Glucagon‑like peptide‑ 1 7– 36: a physiological incretin in man. Lancet 1987; 2: 1300– 1304.

11. Nauck M, Stöckmann F, Ebert R et al. Reduced incretin effect in type 2 (non‑insulin‑dependent) diabetes. Diabetologia 1986; 29: 46– 52.

12. Nauck MA, Weber I, Bach I et al. Normalization of fasting glycaemia by intravenous GLP‑1 ([7– 36 amide] or [7– 37]) in type 2 diabetic patients. Diabet Med 1998; 15: 937– 945.

13. Holst JJ. The physiology of glucagon‑like peptide 1. Physiol Rev 2007; 87: 1409– 1439.

14. Vilsbøll T, Agersø H, Krarup T et al. Similar elimination rates of glucagon‑like peptide‑ 1 in obese type 2 diabetic patients and healthy subjects. J. Clin Endocrinol Metab 2003; 88: 220– 224.

15. Ahrén B. Glucagon‑like peptide‑ 1 (GLP‑1): a gut hormone of potential interest in the treatment of diabetes. Bioessays 1998; 20: 642– 651.

16. Thomsen C, Rasmussen O, Lousen T et al. Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects. Am J Clin Nutr 1999; 69: 1135– 1143.

17. Beysen C, Karpe F, Fielding BA et al. Interaction between specific fatty acids, GLP‑1 and insulin secretion in humans. Diabetologia 2002; 45: 1533– 1541.

18. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon‑like peptide‑ 1 secretion through TGR5 in a murine enteroendocrine cell line STC‑ 1. Biochem Biophys Res Commun 2005; 329: 386– 390.

19. Östman EM, Liljeberg Elmståhl HG, Björck IM.Inconsistency between glycemic and insulinemic responses to regular and fermented milk products. Am J Clin Nutr 2001; 74: 96– 100.

20. Fajans SS, Floyd JC Jr, Knopf RF et al. Effect of amino acids and proteins on insulin secretion in man. Recent Prog Horm Res 1967; 23: 617– 662.

21. van Loon LJ, Kruijshoop M, Verhagen H et al.Ingestion of protein hydrolysate and amino acid‑ carbohydrate mixtures increases postexercise plasma insulin responses in men. J Nutr 2000; 130: 2508– 2513.

22. Nilsson M, Stenberg M, Frid AH et al. Glycemia and insulinemia in healthy subjects after lactose‑equivalent meals of milk and other food proteins: the role of plasma amino acids and incretins. Am J Clin Nutr 2004; 80: 1246– 1253.

23. Frid AH, Nilsson M, Holst JJ et al. Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. Am J Clin Nutr 2005; 82: 69– 75.

24. Mayo KE, Miller LJ, Bataille D et al. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 2003; 55: 167– 194.

25. Drucker DJ, Philippe J, Mojsov S et al. Glucagon‑like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 1987; 84: 3434– 3438.

26. Göke R, Conlon JM. Receptors for glucagon‑like peptide‑ 1(7- 36)amide on rat insulinoma‑ derived cells. J Endocrinol 1988; 116: 357– 362.

27. Körner M, Stöckli M, Waser B et al. GLP‑1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007; 48: 736– 743.

28. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco‑ incretin hormone glucagon‑like peptide 1. Proc Natl Acad Sci USA 1992; 89: 8641– 8645.

29. Thorens B, Porret A, Bühler L et al. Cloning and functional expression of the human islet GLP‑1 receptor. Demonstration that exendin‑4 is an agonist and exendin‑(9-39) an antagonist of the receptor. Diabetes 1993; 42: 1678– 1682.

30. Moens K, Heimberg H, Flamez D et al. Expression and functional activity of glucagon, glucagon‑like peptide I, and glucose‑dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 1996; 45: 257– 261.

31. Tomas E, Habener JF. Insulin‑like actions of glucagon‑like peptide‑ 1: a dual receptor hypothesis. Trends Endocrinol Metab 2010; 21: 59– 67.

32. Samson SL, Bajaj M. Potential of incretin‑based therapies for non‑alcoholic fatty liver disease. J Diabetes Complications 2013. In press.

33. Campos RV, Lee YC, Drucker DJ. Divergent tissue‑ specific and developmental expression of receptors for glucagon and glucagon‑like peptide‑ 1 in the mouse. Endocrinology 1994; 134: 2156– 2164.

34. Egan JM, Montrose‑Rafizadeh C, Wang Y et al. Glucagon‑like peptide‑ 1(7- 36)amide (GLP‑1) enhances insulin‑stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP‑1 action. Endocrinology 1994; 135: 2070– 2075.

35. Ding X, Saxena NK, Lin S et al. Exendin‑4, a glucagon‑like protein‑1 (GLP‑1) receptor agonist, reverses hepatic steatosis in ob/ ob mice. Hepatology 2006; 43: 173– 181.

36. Aviv V, Meivar‑ Levy I, Rachmut IH et al. Exendin‑4 promotes liver cell proliferation and enhances the PDX‑ 1‑induced liver to pancreas transdifferentiation process. J Biol Chem 2009; 284: 33509– 33520.

37. Gupta NA, Mells J, Dunham RM et al. Glucagon‑like peptide‑ 1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010; 51: 1584– 1592.

38. Svegliati‑ Baroni G, Saccomanno S, Rychlicki C et al. Glucagon‑like peptide‑ 1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high‑fat diet in nonalcoholic steatohepatitis. Liver Int 2011; 31: 1285– 1297.

39. Ben‑ Shlomo S, Zvibel I, Shnell M et al. Glucagon‑like peptide‑ 1 reduces hepatic lipogenesis via activation of AMP‑activated protein kinase. J Hepatol 2011; 54: 1214– 1223.

40. Lee J, Hong SW, Chae SW et al. Exendin‑4 improves steatohepatitis by increasing Sirt1 expression in high‑fat diet‑induced obese C57BL/ 6J mice. PLoS One 2012; 7: e31394.

41. Ghiglione M, Blazquez E, Uttenthal LO et al. Glucagon‑like peptide‑ 1 does not have a role in hepatic carbohydrate metabolism. Diabetologia 1985; 28: 920– 921.

42. Blackmore PF, Mojsov S, Exton JH et al. Absence of insulinotropic glucagon‑like peptide‑ I(7– 37) receptors on isolated rat liver hepatocytes. FEBS Lett 1991; 283: 7– 10.

43. Valverde I, Morales M, Clemente F et al. Glucagon‑like peptide 1: a potent glycogenic hormone. FEBS Lett 1994; 349: 313– 316.

44. Wei Y, Mojsov S. Tissue‑ specic expression of the human receptor for glucagon‑like peptide‑ I: brain, heart and pancreatic forms have the same deduced amino‑ acid‑ sequences. FEBS Lett 1995; 358: 219– 224.

45. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon‑like peptide‑ 1 receptor. Endocrinology 1996; 137: 2968– 2978.

46. Dunphy JL, Taylor RG, Fuller PJ. Tissue distribution of rat glucagon receptor and GLP‑1 receptor gene expression. Mol Cell Endocrinol 1998; 141: 179– 186.

47. Flock G, Baggio LL, Longuet C et al. Incretin receptors for glucagon‑like peptide 1 and glucose‑dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 2007; 56: 3006– 3013.

48. Tomas E, Stanojevic V, Habener JF. GLP‑1(9– 36)amide metabolite suppression of glucose production in isolated mouse hepatocytes. Horm Metab Res 2010; 42: 657– 662.

49. Nakagawa A, Satake H, Nakabayashi H et al.Receptor gene expression of glucagon‑like peptide‑ 1, but not glucose‑dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 2004; 110: 36– 43.

50. Vahl TP, Tauchi M, Durler TS et al. Glucagon‑like peptide‑ 1 (GLP‑1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP‑1 on glucose tolerance in rats. Endocrinology 2007; 148: 4965– 4973.

51. Hansen L, Deacon CF, Orskov C et al. Glucagon‑like peptide‑ 1– (7– 36)amide is transformed to glucagon‑like peptide‑ 1– (9– 36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999; 140: 5356– 5363.

52. D‘Alessio D, Vahl T, Prigeon R. Effects of glucagon‑like peptide 1 on the hepatic glucose metabolism. Horm Metab Res 2004; 36: 837– 841.

53. Holst JJ, Deacon CF. Glucagon‑like peptide‑ 1 mediates the therapeutic actions of DPP‑ IV inhibitors. Diabetologia 2005; 48: 612– 615.

54. Hayes MR, De Jonghe BC, Kanoski SE. Role of the glucagon‑like‑ peptide‑ 1 receptor in the control of energy balance. Physiol Behav 2010; 100: 503– 510.

55. Hayes MR, Kanoski SE, De Jonghe BC et al.The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon‑like‑ peptide‑ 1. Am J Physiol Regul Integr Comp Physiol 2011; 301: R1479– R1485.

56. Hayes MR. Neuronal and intracellular signaling pathways mediating GLP‑1 energy balance and glycemic effects. Physiol Behav 2012; 106: 413– 416.

57. Boyle PJ, Liggett SB, Shah SD et al. Direct muscarinic cholinergic inhibition of hepatic glucose production in humans. J Clin Invest 1988; 82: 445– 449.

58. Hansen L, Hartmann B, Bisgaard T et al. Somatostatin restrains the secretion of glucagon‑like peptide‑ 1 and 2 from isolated perfused porcine ileum. Am J Physiol Endocrinol Metab 2000; 278: E1010– E1018.

59. Deacon CF, Pridal L, Klarskov L et al. Glucagon‑like peptide 1 undergoes differential tissue‑ specific metabolism in the anesthetized pig. Am J Physiol 1996; 271: E458– E464.

60. Orskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon‑like peptide‑ 1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 1996; 31: 665– 670.

61. Elahi D, Egan JM, Shannon RP et al. Glucagon‑like peptide‑ 1(9– 36)amide, cleavage product of glucagon‑like peptide‑ 1(7– 36)amide, is a glucoregulatory peptide. Obesity (Silver Spring) 2008; 16: 1501– 1509.

62. Tomas E, Wood JA, Stanojevic V et al. Glucagon‑like peptide‑ 1(9– 36)amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet‑induced obese mice. Diabetes Obes Metab 2011; 13: 26– 33.

63. Tomas E, Wood JA, Stanojevic V et al. GLP‑1- derived nonapeptide GLP‑1(28– 36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet‑induced obese mice. Regul Pept 2011; 169: 43– 48.

64. Tomas E, Stanojevic V, Habener JF. GLP‑1– derived nonapeptide GLP‑1(28– 36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. Regul Pept 2011; 167: 177– 184.

65. Nikolaidis LA, Elahi D, Shen YT et al. Active metabolite of GLP‑1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005; 289: H2401– H2408.

66. Sonne DP, Engstrøm T, Treiman M. Protective effects of GLP‑1 analogues exendin‑4 and GLP‑1(9– 36)amide against ischemia‑ reperfusion injury in rat heart. Regul Pept 2008; 146: 243– 249.

67. Ban K, Noyan‑ Ashraf MH, Hoefer J et al. Cardioprotective and vasodilatory actions of glucagon‑like peptide 1 receptor are mediated through both glucagon‑like peptide 1 receptor‑ dependent and - independent pathways. Circulation 2008; 117: 2340– 2350.

68. Green BD, Hand KV, Dougan JE et al. GLP‑1 and related peptides cause concentration‑ dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 2008; 478: 136– 142.

69. Alcántara AI, Morales M, Delgado E et al. Exendin‑4 agonist and exendin(9– 39)amide antagonist of the GLP‑1(7– 36)amide effects in liver and muscle. Arch Biochem Biophys 1997; 341: 1– 7.

70. López‑ Delgado MI, Morales M, Villanueva‑ Peñacarrillo ML et al. Effects of glucagon‑like peptide 1 on the kinetics of glycogen synthase a in hepatocytes from normal and diabetic rats. Endocrinology 1998; 139: 2811– 2817.

71. Egan JM, Meneilly GS, Habener JF et al. Glucagon‑like peptide‑ 1 augments insulin‑mediated glucose uptake in the obese state. J Clin Endocrinol Metab 2002; 87: 3768– 3773.

72. Dardevet D, Moore MC, Neal D et al. Insulin‑independent effects of GLP‑1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region. Am J Physiol Endocrinol Metab 2004; 287: E75– E81.

73. Deacon CF, Plamboeck A, Møller S et al. GLP‑1(9– 36)amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. Am J Physiol Endocrinol Metab 2002; 282: E873– E879.

74. Meier JJ, Gethmann A, Nauck MA et al.The glucagon‑like peptide‑ 1 metabolite GLP‑1(9– 36)amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. Am J Physiol Endocrinol Metab 2006; 290: E1118– E1123.

75. Vahl TP, Paty BW, Fuller BD et al. Effects of GLP‑1- (7– 36)NH2, GLP‑1– (7– 37), and GLP‑1- (9– 36)NH2 on intravenous glucose tolerance and glucose‑induced insulin secretion in healthy humans. J Clin Endocrinol Metab 2003; 88: 1772– 1779.

76. Lee J, Hong SW, Rhee EJ et al. GLP‑1 Receptor Agonist and Non‑ Alcoholic Fatty Liver Disease. Diabetes Metab J 2012; 36: 262– 267.

77. Samson SL, Gonzalez EV, Yechoor V et al. Gene therapy for diabetes: metabolic effects of helper‑ dependent adenoviral exendin 4 expres­sion in a diet‑induced obesity mouse model. Mol Ther 2008; 16: 1805– 1812.

78. Samson SL, Sathyanarayana P, Jogi M et al. Exenatide decreases hepatic broblast growth factor 21 resistance in non‑alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia 2011; 54: 3093– 3100.

79. Sharma S, Mells JE, Fu PP et al. GLP‑1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One 2011; 6: e25269.

80. Trevaskis JL, Griffin PS, Wittmer C et al. Glucagon‑like peptide‑ 1 receptor agonism improves metabolic, bio­chemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 2012; 302: G762– G772.

81. Shirakawa J, Fujii H, Ohnuma K et al. Diet‑induced adipose tissue inammation and liver steatosis are prevented by DPP‑ 4 inhibition in diabetic mice. Diabetes 2011; 60: 1246– 1257.

82. Ben‑ Shlomo S, Zvibel I, Rabinowich L et al. Dipeptidyl peptidase 4– deficient rats have improved bile secretory function in high fat diet‑induced steatosis. Dig Dis Sci 2013; 58: 172– 178.

83. Mells JE, Fu PP, Sharma S et al. Glp‑ 1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/ 6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol 2012; 302: G225– G235.

84. Tushuizen ME, Bunck MC, Pouwels PJ et al.Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006; 26: 1015– 1017.

85. Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic bio­markers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 275– 286.

86. D’Amico E. Efficacy of liraglutide in a patient with type 2 diabetes and cryptogenic cirrhosis. Acta Biomed 2011; 82: 160– 161.

87. Sathyanarayana P, Jogi M, Muthupillai R et al. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity 2011; 19: 2310– 2315.

88. Vilsbøll T, Christensen M, Junker AE et al. Effects of glucagon‑like peptide‑ 1 receptor agonists on weight loss: systematic review and meta‑analyses of randomised controlled trials. BMJ 2012; 344: d7771.

89. Ohki T, Isogawa A, Iwamoto M et al. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. Scientific World Journal 2012; 2012: 496453.

90. Cuthbertson DJ, Irwin A, Gardner CJ et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon‑like peptide‑ 1 (GLP‑1) receptor agonists. PLoS One 2012; 7: e50117.

91. Kenny PR, Brady DE, Torres DM et al. Exenatide in the treatment of diabetic patients with non‑alcoholic steatohepatitis: a case series. Am J Gastroenterol 2010; 105: 2707– 2709.

92. Buse JB, Klonoff DC, Nielsen LL et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic bio­markers in patients with type 2 diabetes: an interim analysis of data from the open‑ label, uncontrolled extension of three double‑blind, placebo‑ controlled trials. Clin Ther 2007; 29: 139– 153.

93. Pizarro M, Balasubramaniyan N, Solís N et al.Bile secretory function in the obese Zucker rat: evidence of cholestasis and altered canalicular transport function. Gut 2004; 53: 1837– 1843.

94. Ruhl CE, Everhart JE. Epidemiology of nonalcoholic fatty liver. Clin Liver Dis 2004; 8: 501– 519.

95. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008; 75: 721– 728.

96. Vanni E, Bugianesi E, Kotronen A et al. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010; 42: 320– 330.

97. Haluzik M, Rychlik I et al. Léčba diabetu u pacientů s onemocněním ledvin a jater. Praha: Mladá Fronta 2012.

Diabetology Endocrinology Internal medicine
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account